Developer docs
API playgroundTry for free, no card

Search company profiles

Coapt

Full company profile

uuid000a5fd

Namestring
Coapt
Legal namestring
Coapt, LLC
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Coapt is a Chicago-based medical device company founded in 2012 that develops myoelectric pattern recognition technology for upper limb prosthetics. Its flagship product, Complete Control Gen2, is an FDA Class II-cleared controller kit that uses machine learning algorithms to decode electromyographic (EMG) signals from residual limb muscles in real time and translate user intent into intuitive prosthetic arm and hand movements. The system is device-agnostic, compatible with 400-450+ upper-limb prosthesis configurations from manufacturers including Ottobock, Össur, TASKA, bebionic, Vincent, and Esper, and is paired with the Control Coach AI companion and the Control Companion mobile app (iOS/Android) for in-clinic setup and on-the-go calibration. Coapt sells primarily through prosthetic clinics and licensed prosthetists, licenses its technology to OEMs for integration, and supplements revenue with federally funded research grants; the firm operates a Boston-area R&D subsidiary, Liberating Technologies, Inc.

The company's go-to-market spans clinical, OEM, and government channels: direct sales to prosthetists via a 1-844 contact line, OEM integration partnerships across the major upper-limb manufacturers, and DoD-funded research programs (notably a $2.3M RESTORE grant in 2020 for VR-based phantom limb pain therapy). Products are commercially available in the United States, Canada, Australia, New Zealand, and across much of Europe. In January 2025, Coapt secured HCPCS Code L6700 — the first dedicated reimbursement code for advanced pattern-recognition prosthetic control — and in February 2025 announced an agreement to be acquired by Hanger, Inc., the largest U.S. orthotic and prosthetic provider with 900+ clinic locations; the transaction was expected to close in Q1 2025 and would substantially broaden clinical access to Coapt's technology.

Short descriptiontext

Coapt develops FDA-cleared myoelectric pattern recognition software and hardware that translate muscle signals into intuitive prosthetic arm and hand movements, sold to prosthetists, clinics, and OEM partners globally. The Chicago-based firm was acquired by Hanger, Inc. in 2025.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersChicago, United States
HQ citystring
Chicago
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
myoelectric pattern recognition, prosthetic control systems, upper limb prosthetics, human-machine interfaces, medical device technology
Industry2 codes
PRIMARYHLAHAEAH
Limb Prosthetics (Upper/Lower Extremity Prosthetic Systems)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHAMAD
Prosthetic Components & Rehabilitation Accessories (Liners, Feet, Knees, Sockets)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Rehabilitation & Mobility Aids (DME)
NAICS code2 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Upper-Limb Prosthetic Control Systems
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Complete Control Gen2 System Sales
TypeHardware Sales
Description

Coapt sells the Complete Control Gen2 hardware system — an add-on intent decoder controller kit — to prosthetists and clinics. The system is billed under HCPCS code L6700 (effective April 1, 2025) for Medicare and other health insurance reimbursement. CMS payment is made on a purchase basis.

coaptengineering.com
2Licensing & Integration Partnerships
TypeLicensing Royalties
Description

Coapt licenses its pattern recognition technology to prosthetic device manufacturers, enabling integration of its intent decoding system into their prosthetic arms and hands. The company works with product manufacturers to incorporate its technology into myoelectric prostheses.

coaptengineering.com
3Mobile Application (Control Companion)
TypeFreemium
Description

The Control Companion mobile app provides additional functionality for users and clinicians, available on iOS and Android app stores. The app includes training tools, games, and Control Coach AI integration.

coaptengineering.com
4Government Research Grants
TypeProfessional Services
Description

Coapt receives federally funded research grants, including a $2.3M Department of Defense RESTORE grant for VR-based phantom limb pain therapy development. LTI has received over 45 federally funded research awards totaling over $24.9M. These are non-dilutive funding sources.

coaptengineering.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Complete Control Gen2 System (L6700)
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

HCPCS Code L6700 — Upper extremity addition, external powered feature, myoelectronic control module, additional EMG inputs, pattern-recognition decoding intent movement. Effective April 1, 2025. CMS reimbursement on purchase basis. Check PDAC fee schedule for state-specific allowable amounts. Full pricing not publicly disclosed; requires direct quote from sales.

coaptengineering.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Complete Control Gen2
Description

Best-in-class pattern recognition intent decoding technology for upper limb prosthesis wearers. An add-on controller kit offering unprecedented intuitiveness for patient lifestyles.

coaptengineering.com
+2 more records
Core offering1 text field

Coapt designs, manufactures, and sells the Complete Control Gen2 system, an FDA Class II-cleared add-on controller kit that uses machine-learning pattern recognition to decode myoelectric (EMG) signals from a user's residual limb muscles and translate them into intuitive movements of a powered upper-limb prosthesis. The kit is paired with the Control Coach AI companion and the Control Companion iOS/Android mobile app, is device-agnostic across 400+ upper-limb prosthesis configurations, and is sold primarily to certified prosthetists and O&P clinics while also being licensed to prosthetic component manufacturers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 400+ upper-limb prosthesis combinations supported
+2 more records
Product overview1 text field

Coapt offers a unified product ecosystem centered on its Complete Control Gen2 pattern recognition technology for upper limb prosthetic control. The core offering is the Complete Control system—an FDA Class II-cleared myoelectric, machine learning prosthesis control system that decodes user intent from muscle signals. This integrates with the Control Coach AI companion for intelligent calibration guidance and the Control Companion mobile app for on-the-go refinement. Coapt's technology is device-agnostic, compatible with over 400 upper-limb prosthesis configurations from manufacturers including Ottobock, Össur, TASKA, and others. The company operates through its main Chicago headquarters and research subsidiary Liberating Technologies, Inc. in Boston, and was acquired by Hanger, Inc. in 2025.

Product and service5 records
1Complete Control Gen2
CategoryMedical Device / Prosthetic Control System
Description

FDA Class II-cleared, add-on pattern-recognition controller kit that decodes myoelectric (EMG) signals from residual limb muscles using machine-learning algorithms and translates user intent into intuitive movements of a powered upper-limb prosthesis. Device-agnostic across 400+ upper-limb prosthesis configurations. Sold primarily to certified prosthetists and O&P clinics and reimbursed under HCPCS L6700.

2Control Coach AI Companion
CategoryAI Software / Digital Health Companion
Description

AI-powered companion embedded in the Gen2 system that analyzes how users personalize their intent decoding, provides 5-star quality ratings across data sufficiency, specificity, repeatability, robustness, and intensity, and delivers corrective suggestions to optimize prosthetic control. Designed for both clinicians and end users.

3Control Companion Mobile App
CategoryMobile Software Application
Description

iOS and Android mobile app distributed via the App Store (id 1578333990) and Google Play store that serves as the central hub for clinicians and end users for in-clinic setup, calibration controls, Adaptive Advance controls, save/restore of calibrations, training tools and games, and Control Coach AI integration.

4ControlSeal Electrode Dome
CategoryProsthetic Accessory / Electrode Component
Description

Proprietary electrode dome accessory for the Complete Control Gen2 system designed to maintain consistent skin contact for reliable myoelectric signal capture during calibration and daily use.

5Complete Control Room v2 Application
CategoryClinician Software / Desktop Application
Description

Desktop clinician application used to configure and manage Coapt Complete Control prosthetic control systems, distributed under an End User License Agreement.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-02-20
Description

Hanger, Inc. — a leading provider of orthotic and prosthetic patient care services with 900+ Hanger Clinic locations nationwide — announced an agreement to acquire Coapt. Hanger's CEO Pete Stoy stated the technology is a natural complement to Hanger's focus on bringing innovation to patient care. The acquisition was expected to close in Q1 2025. Hanger's manufacturing capability and clinic footprint is expected to strengthen Coapt's products and broaden their use.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-05-08
Description

Coapt collaborated with WillowWood Global to release the Alpha Control Liner System — the first prosthetic liner with embedded electronics. The liner captures and conditions muscle contraction signals and communicates seamlessly with Coapt's Complete Control myoelectric pattern recognition system. The partnership was described as combining revolutionary liner technology with best-in-class myoelectric technology to define the new gold standard for prosthesis control. The collaboration was funded in part by a Department of Defense clinical trial.

Strategic tierCoreTypeOthersAnnounced on2021-07-14
Description

Coapt acquired Liberating Technologies, a prosthetics developer based in Holliston, MA (previously owned by College Park Industries). LTI serves as Coapt's research and development subsidiary, headquartered in the Boston area. Todd Farrell, Ph.D. was named CEO of LTI in June 2023. LTI has secured over 45 federally funded research awards totaling over $24.9M.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers13 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Coapt

Upper-Limb Prosthetic Control Systemscoaptengineering.com

Coapt develops FDA-cleared myoelectric pattern recognition software and hardware that translate muscle signals into intuitive prosthetic arm and hand movements, sold to prosthetists, clinics, and OEM partners globally. The Chicago-based firm was acquired by Hanger, Inc. in 2025.

What Coapt does

Coapt is a Chicago-based medical device company founded in 2012 that develops myoelectric pattern recognition technology for upper limb prosthetics. Its flagship product, Complete Control Gen2, is an FDA Class II-cleared controller kit that uses machine learning algorithms to decode electromyographic (EMG) signals from residual limb muscles in real time and translate user intent into intuitive prosthetic arm and hand movements. The system is device-agnostic, compatible with 400-450+ upper-limb prosthesis configurations from manufacturers including Ottobock, Össur, TASKA, bebionic, Vincent, and Esper, and is paired with the Control Coach AI companion and the Control Companion mobile app (iOS/Android) for in-clinic setup and on-the-go calibration. Coapt sells primarily through prosthetic clinics and licensed prosthetists, licenses its technology to OEMs for integration, and supplements revenue with federally funded research grants; the firm operates a Boston-area R&D subsidiary, Liberating Technologies, Inc.

The company's go-to-market spans clinical, OEM, and government channels: direct sales to prosthetists via a 1-844 contact line, OEM integration partnerships across the major upper-limb manufacturers, and DoD-funded research programs (notably a $2.3M RESTORE grant in 2020 for VR-based phantom limb pain therapy). Products are commercially available in the United States, Canada, Australia, New Zealand, and across much of Europe. In January 2025, Coapt secured HCPCS Code L6700 — the first dedicated reimbursement code for advanced pattern-recognition prosthetic control — and in February 2025 announced an agreement to be acquired by Hanger, Inc., the largest U.S. orthotic and prosthetic provider with 900+ clinic locations; the transaction was expected to close in Q1 2025 and would substantially broaden clinical access to Coapt's technology.

Coapt firmographics

Firmographics
Name
Coapt
Legal name
Coapt, LLC
Website
https://coaptengineering.com
Company type
Private
Founded year
2012
Operating status
Acquired
Headcount range
11–50 employees
Short description
Coapt develops FDA-cleared myoelectric pattern recognition software and hardware that translate muscle signals into intuitive prosthetic arm and hand movements, sold to prosthetists, clinics, and OEM partners globally. The Chicago-based firm was acquired by Hanger, Inc. in 2025.
Ownership category
akta.pro rank

Coapt industry classification

Industry
Product category
Upper-Limb Prosthetic Control Systems
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAEAH
Limb Prosthetics (Upper/Lower Extremity Prosthetic Systems)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHAMAD
Prosthetic Components & Rehabilitation Accessories (Liners, Feet, Knees, Sockets)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Rehabilitation & Mobility Aids (DME)

Keywords

  • Myoelectric pattern recognition
  • Prosthetic control systems
  • Upper limb prosthetics
  • Human-machine interfaces
  • Medical device technology

Where Coapt is headquartered

Location

Headquarters

HQ city
Chicago
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Coapt business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Complete Control Gen2 System Sales: Coapt sells the Complete Control Gen2 hardware system — an add-on intent decoder controller kit — to prosthetists and clinics. The system is billed under HCPCS code L6700 (effective April 1, 2025) for Medicare and other health insurance reimbursement. CMS payment is made on a purchase basis.
  2. Licensing & Integration Partnerships: Coapt licenses its pattern recognition technology to prosthetic device manufacturers, enabling integration of its intent decoding system into their prosthetic arms and hands. The company works with product manufacturers to incorporate its technology into myoelectric prostheses.
  3. Mobile Application (Control Companion): The Control Companion mobile app provides additional functionality for users and clinicians, available on iOS and Android app stores. The app includes training tools, games, and Control Coach AI integration.
  4. Government Research Grants: Coapt receives federally funded research grants, including a $2.3M Department of Defense RESTORE grant for VR-based phantom limb pain therapy development. LTI has received over 45 federally funded research awards totaling over $24.9M. These are non-dilutive funding sources.

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goComplete Control Gen2 System (L6700)

Go-to-market motion3 records

Distribution channels4 records

Marketing channels8 records

Coapt product offering

Product offering

Core offering

Coapt designs, manufactures, and sells the Complete Control Gen2 system, an FDA Class II-cleared add-on controller kit that uses machine-learning pattern recognition to decode myoelectric (EMG) signals from a user's residual limb muscles and translate them into intuitive movements of a powered upper-limb prosthesis. The kit is paired with the Control Coach AI companion and the Control Companion iOS/Android mobile app, is device-agnostic across 400+ upper-limb prosthesis configurations, and is sold primarily to certified prosthetists and O&P clinics while also being licensed to prosthetic component manufacturers.

Product overview

Coapt offers a unified product ecosystem centered on its Complete Control Gen2 pattern recognition technology for upper limb prosthetic control. The core offering is the Complete Control system—an FDA Class II-cleared myoelectric, machine learning prosthesis control system that decodes user intent from muscle signals. This integrates with the Control Coach AI companion for intelligent calibration guidance and the Control Companion mobile app for on-the-go refinement. Coapt's technology is device-agnostic, compatible with over 400 upper-limb prosthesis configurations from manufacturers including Ottobock, Össur, TASKA, and others. The company operates through its main Chicago headquarters and research subsidiary Liberating Technologies, Inc. in Boston, and was acquired by Hanger, Inc. in 2025.

Differentiator

Problem solved

Functional benefit

Brands

  • Complete Control Gen2: Best-in-class pattern recognition intent decoding technology for upper limb prosthesis wearers. An add-on controller kit offering unprecedented intuitiveness for patient lifestyles.
  • Control Coach
  • Control Companion

Products and services

  • Complete Control Gen2 FDA Class II-cleared, add-on pattern-recognition controller kit that decodes myoelectric (EMG) signals from residual limb muscles using machine-learning algorithms and translates user intent into intuitive movements of a powered upper-limb prosthesis. Device-agnostic across 400+ upper-limb prosthesis configurations. Sold primarily to certified prosthetists and O&P clinics and reimbursed under HCPCS L6700.
  • Control Coach AI Companion AI-powered companion embedded in the Gen2 system that analyzes how users personalize their intent decoding, provides 5-star quality ratings across data sufficiency, specificity, repeatability, robustness, and intensity, and delivers corrective suggestions to optimize prosthetic control. Designed for both clinicians and end users.
  • Control Companion Mobile App iOS and Android mobile app distributed via the App Store (id 1578333990) and Google Play store that serves as the central hub for clinicians and end users for in-clinic setup, calibration controls, Adaptive Advance controls, save/restore of calibrations, training tools and games, and Control Coach AI integration.
  • ControlSeal Electrode Dome Proprietary electrode dome accessory for the Complete Control Gen2 system designed to maintain consistent skin contact for reliable myoelectric signal capture during calibration and daily use.
  • Complete Control Room v2 Application Desktop clinician application used to configure and manage Coapt Complete Control prosthetic control systems, distributed under an End User License Agreement.

Quantifiable outcome

  • 400+ upper-limb prosthesis combinations supported
  • +2 more outcomes

Companies that use Coapt

Customer profile

Named customers13 records

Segments4 records

Ideal customer profiles3 records

Coapt technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability3 records

Feature6 records

Coapt partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered flagship and core.

  • Hanger, Inc.flagshipStrategic or Co-development Partner · 20 February 2025Hanger, Inc. — a leading provider of orthotic and prosthetic patient care services with 900+ Hanger Clinic locations nationwide — announced an agreement to acquire Coapt. Hanger's CEO Pete Stoy stated the technology is a natural complement to Hanger's focus on bringing innovation to patient care. The acquisition was expected to close in Q1 2025. Hanger's manufacturing capability and clinic footprint is expected to strengthen Coapt's products and broaden their use.
  • WillowWood Global LLCcoreStrategic or Co-development Partner · 8 May 2023Coapt collaborated with WillowWood Global to release the Alpha Control Liner System — the first prosthetic liner with embedded electronics. The liner captures and conditions muscle contraction signals and communicates seamlessly with Coapt's Complete Control myoelectric pattern recognition system. The partnership was described as combining revolutionary liner technology with best-in-class myoelectric technology to define the new gold standard for prosthesis control. The collaboration was funded in part by a Department of Defense clinical trial.
  • Liberating Technologies, Inc. (LTI)coreOthers · 14 July 2021Coapt acquired Liberating Technologies, a prosthetics developer based in Holliston, MA (previously owned by College Park Industries). LTI serves as Coapt's research and development subsidiary, headquartered in the Boston area. Todd Farrell, Ph.D. was named CEO of LTI in June 2023. LTI has secured over 45 federally funded research awards totaling over $24.9M.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Coapt competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Coapt social profiles

Digital presence

Coapt compliance and trust

Trust signal

Compliance2 records

Coapt financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Coapt leadership team

Management profile

Number of profiles

Profiles3 records

Coapt subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Coapt funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Coapt M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Coapt

What does Coapt do?

Coapt designs, manufactures, and sells the Complete Control Gen2 system, an FDA Class II-cleared add-on controller kit that uses machine-learning pattern recognition to decode myoelectric (EMG) signals from a user's residual limb muscles and translate them into intuitive movements of a powered upper-limb prosthesis. The kit is paired with the Control Coach AI companion and the Control Companion iOS/Android mobile app, is device-agnostic across 400+ upper-limb prosthesis configurations, and is sold primarily to certified prosthetists and O&P clinics while also being licensed to prosthetic component manufacturers.

Is Coapt a public or private company?

Coapt is a private company. It is classified as corporate owned and is currently acquired.

When was Coapt founded?

Coapt was founded in 2012. It employs 11 to 50 people.

Where is Coapt based?

Coapt is headquartered in Chicago, United States, in the North America region.

How does Coapt make money?

Four revenue lines are on record. Complete Control Gen2 System Sales are the primary driver. The others are licensing & Integration Partnerships, mobile Application (Control Companion) and government Research Grants.

Does Coapt have an API?

No public API is recorded for Coapt.

What industry is Coapt in?

Coapt's product category is Upper-Limb Prosthetic Control Systems. Its primary akta.pro industry code is HLAHAEAH, Limb Prosthetics (Upper/Lower Extremity Prosthetic Systems), with a secondary code of HLAHAMAD, Prosthetic Components & Rehabilitation Accessories (Liners, Feet, Knees, Sockets). Its NAICS code is 339113 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comRobotic Prosthetics Market to Reach USD 2.2 Billion by 2035 Driven by AI-Powered Bionic Limbs and Smart Rehabilitation TechnologiesAccording to a MarketGenics report published May 15, 2026, the global robotic prosthetics market is projected to grow from USD 0.6 billion in 2025 to USD 2.2 billion by 2035, representing a CAGR of 12.3%. The report identifies key growth drivers including rising limb loss from diabetes and vascular diseases, increasing demand for rehabilitation technologies, and advancements in sensor and actuator technologies for prosthetics, with WHO estimating over 40 million amputees worldwide. In specific product developments, Össur launched an AI-powered bionic leg in May 2025 and Coapt LLC introduced EMG sensor-integrated arm prosthetic controllers in March 2025.Market Report AnalyticsIntelligent Bionic Prosthesis Future Pathways: Strategic Insights to 2033The global intelligent bionic prosthesis market is projected to grow from approximately USD 891 million in 2025 to over USD 7.5 billion by 2030, driven by advancements in AI, robotics, and sensor technology, with a CAGR of 6.1% to 12.5% depending on the forecast period referenced. North America, led by the United States, is expected to dominate the market due to high healthcare spending, advanced infrastructure, and significant R&D investment, while the upper limbs segment is projected to exhibit the most substantial growth due to the complexity of restoring fine motor skills. Major players including Össur and Ottobock collectively hold an estimated 35-40% of the global market share, though innovative companies such as Coapt, LLC and Open Bionics are rapidly gaining traction by focusing on advanced control systems and affordable, 3D-printed solutions respectively.PR NewswireCoapt Acquires Liberating Technologies, Inc., from College Park IndustriesCoapt announced its acquisition of Liberating Technologies, Inc. from College Park Industries on July 14, 2021. This acquisition aims to enhance Coapt's research and development capabilities in the field of orthotics and prosthetics. Additionally, the collaboration is expected to advance the development of innovative technologies that benefit individuals with limb loss or limb differences.American City Business JournalsChicago firm acquires Holliston prosthetics developer Liberating TechnologiesChicago-based firm Coapt has acquired Holliston prosthetics developer Liberating Technologies, Inc., marking the company's second acquisition since being bought by College Park Industries six years ago. The transaction represents a strategic transfer of ownership for the prosthetics manufacturer to a new entity focused on this sector.PR NewswireDepartment of Defense awards tech firm Coapt $2.3M to develop virtual reality-based therapy to ease phantom limb painThe Department of Defense awarded Chicago-based Coapt a $2.3 million grant to develop virtual reality and hardware-based therapies for treating phantom limb pain in amputees. This funding supports the fourth-year study of Coapt's existing VR rehabilitation technology, aiming to create a commercially viable product for both veterans and civilians.PR NewswireCoapt Now First and Only Advanced Myoelectric Control System with FDA Class II ClearanceCoapt, LLC announced it received FDA Class II medical device clearance for its COMPLETE CONTROL System, a myoelectric pattern recognition technology for advanced prosthetic arms. The system is the first and only myoelectric pattern recognition device cleared for marketing in the United States, using electrical signals from remaining muscles to enable intuitive prosthetic control. Coapt, founded in 2012 and based on research from the Shirley Ryan AbilityLab, serves the over 100,000 upper-limb amputees in the United States.IEEE SpectrumBionic Arms Get a Thought-Control UpgradeCoapt introduced a prosthetic control system using pattern recognition to decode muscle signals, allowing more natural movement. The system is compatible with major manufacturers and is used by about 200 individuals. A smaller second-generation device is planned, with future research on implantable electrodes.ABC7 ChicagoChicago networking service helps moms rejoin workforceThe Mom Project, a Chicago networking service, helps moms and some dads find flexible, part-time work. It has 5,000 applicants and 100 registered businesses since April. Coapt Engineering used it to find Melina Harvey-Read for bookkeeping.PR NewswireCoapt signs exclusive license with Purdue to revolutionize bionic limb controlCoapt, a Chicago-based company specializing in intuitive control systems for advanced prosthetic arms, announced on March 8, 2016, that it has obtained an exclusive license for implantable electrode technology from Purdue Research Foundation. The technology, which uses electrodes implanted under the skin to read electrical signals more clearly than surface sensors, is expected to significantly advance prosthetic limb control for the more than 100,000 upper-limb amputees in the United States. Coapt, founded in 2012 and based on research from the Rehabilitation Institute of Chicago, positioned this deal as a strategic expansion that solidifies its position as the industry leader in bionic limb technology.